Cargando…

Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model

Previous studies reported that diabetes alters the activities of hepatic cytochrome P450 (CYP) enzymes, which, in turn, affects the disposition of some drugs. We herein examined and compared the effects of the combination of dapagliflozin with a low insulin dose, a full dose of insulin alone, and da...

Descripción completa

Detalles Bibliográficos
Autores principales: SAYED, Noha, MURATA, Ikue, ABDALLA, Osama, KILANY, Omnia, DESSOUKI, Amina, SASAKI, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569876/
https://www.ncbi.nlm.nih.gov/pubmed/34483187
http://dx.doi.org/10.1292/jvms.21-0249
_version_ 1784594730947969024
author SAYED, Noha
MURATA, Ikue
ABDALLA, Osama
KILANY, Omnia
DESSOUKI, Amina
SASAKI, Kazuaki
author_facet SAYED, Noha
MURATA, Ikue
ABDALLA, Osama
KILANY, Omnia
DESSOUKI, Amina
SASAKI, Kazuaki
author_sort SAYED, Noha
collection PubMed
description Previous studies reported that diabetes alters the activities of hepatic cytochrome P450 (CYP) enzymes, which, in turn, affects the disposition of some drugs. We herein examined and compared the effects of the combination of dapagliflozin with a low insulin dose, a full dose of insulin alone, and dapagliflozin alone for 3 and 8 weeks on CYP activities in a diabetes type 1 rat model. We induced type 1 diabetes in rats using a single intraperitoneal injection of 60 mg/kg streptozotocin (STZ). Daily treatment with the full dose of insulin alone, dapagliflozin alone, or dapagliflozin in combination with a low dose of insulin was then initiated. STZ-induced rats developed marked hyperglycemia and altered CYP2E activities. Dapagliflozin in combination with a low dose of insulin stabilized hyperglycemia and CYP1A, 2D, 2E and 3A activities. However, dapagliflozin alone did not improve blood glucose levels or CYP activities. These results suggest that the effects of dapagliflozin in combination with a low dose of insulin are similar to those of a full dose of insulin, and stabilize CYP activities in type 1 diabetes.
format Online
Article
Text
id pubmed-8569876
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Veterinary Science
record_format MEDLINE/PubMed
spelling pubmed-85698762021-11-10 Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model SAYED, Noha MURATA, Ikue ABDALLA, Osama KILANY, Omnia DESSOUKI, Amina SASAKI, Kazuaki J Vet Med Sci Pharmacology Previous studies reported that diabetes alters the activities of hepatic cytochrome P450 (CYP) enzymes, which, in turn, affects the disposition of some drugs. We herein examined and compared the effects of the combination of dapagliflozin with a low insulin dose, a full dose of insulin alone, and dapagliflozin alone for 3 and 8 weeks on CYP activities in a diabetes type 1 rat model. We induced type 1 diabetes in rats using a single intraperitoneal injection of 60 mg/kg streptozotocin (STZ). Daily treatment with the full dose of insulin alone, dapagliflozin alone, or dapagliflozin in combination with a low dose of insulin was then initiated. STZ-induced rats developed marked hyperglycemia and altered CYP2E activities. Dapagliflozin in combination with a low dose of insulin stabilized hyperglycemia and CYP1A, 2D, 2E and 3A activities. However, dapagliflozin alone did not improve blood glucose levels or CYP activities. These results suggest that the effects of dapagliflozin in combination with a low dose of insulin are similar to those of a full dose of insulin, and stabilize CYP activities in type 1 diabetes. The Japanese Society of Veterinary Science 2021-09-06 2021-10 /pmc/articles/PMC8569876/ /pubmed/34483187 http://dx.doi.org/10.1292/jvms.21-0249 Text en ©2021 The Japanese Society of Veterinary Science https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Pharmacology
SAYED, Noha
MURATA, Ikue
ABDALLA, Osama
KILANY, Omnia
DESSOUKI, Amina
SASAKI, Kazuaki
Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title_full Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title_fullStr Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title_full_unstemmed Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title_short Effects of dapagliflozin in combination with insulin on cytochrome P450 activities in a diabetes type 1 rat model
title_sort effects of dapagliflozin in combination with insulin on cytochrome p450 activities in a diabetes type 1 rat model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569876/
https://www.ncbi.nlm.nih.gov/pubmed/34483187
http://dx.doi.org/10.1292/jvms.21-0249
work_keys_str_mv AT sayednoha effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel
AT murataikue effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel
AT abdallaosama effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel
AT kilanyomnia effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel
AT dessoukiamina effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel
AT sasakikazuaki effectsofdapagliflozinincombinationwithinsulinoncytochromep450activitiesinadiabetestype1ratmodel